0 citations
First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2
SSRN Electronic Journal2021
Citations Over Time
Keith J. Chappell, Francesca L. Mordant, Zheyi Li, Danushka K. Wijesundara, Paula Ellenberg, Julia Lackenby, Stacey T. M. Cheung, Naphak Modhiran, Michael S. Avumegah, Christina L Henderson, Kym Hoger, Jillian Bennet, Luca Hensen, Thi H. O. Nguyen, Sara Marrero‐Hernández, Kevin J. Selva, Amy W. Chung, Mai H. Tran, Peter Tapley, Patrick C. Reading, Suellen Nicholson, Stavroula Corby, Thomas Holgate, Bruce D. Wines, P. Mark Hogarth, Katherine Kedzierska, Damian F. J. Purcell, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro
Related Papers
- → Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M(2000)141 cited
- → Prediction of Immunogenicity of Therapeutic Proteins(2010)102 cited
- → The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 gp41(2005)13 cited
- [COMPARATIVE IMMUNOGENICITY STUDIES OF ADJUVANTS FROM VARIOUS SOURCES AND WITH DIFFERENT MECHANISMS OF ACTION FOR INACTIVATED INFLUENZA VACCINES].(2016)
- DDA is More Efficacious Than MPL as Adjuvants That Enhanced Immunogenicity and Protection of Combined DNA Vaccine Against Mycobacterium tuberculosisa(2005)